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Abstract
Intensive care unit (ICU)-acquired infections as a result of multi-
drug-resistant Gram-negative pathogens remain a serious prob-
lem in critically ill patients. Adult ICU patients who received
intravenous fosfomycin were prospectively examined to assess
its safety and effectiveness as an adjunct to the antimicrobial
therapy of life-threatening infections caused by carbapenem-
resistant Klebsiella pneumoniae. Fosfomycin was administered
intravenously in 11 patients for treatment of hospital-acquired
infections caused by carbapenem-resistant K. pneumoniae. Fosfo-
mycin (2–4 g every 6 h) was administered in combination with
other antibiotics. The mean ± SD duration of treatment was
14 ± 5.6 days. All patients had good bacteriological and clinical
outcome of infection. All-cause hospital mortality was two out
of 11 (18.2%) patients. No patient experienced adverse events
related to the administration of fosfomycin. Intravenous fosfomy-
cin may be a beneﬁcial and safe adjunctive treatment in the man-
agement of life-threatening ICU-acquired infections caused by
carbapenem-resistant K. pneumoniae.
Keywords: Carbapenem-resistant Klebsiella pneumoniae, colistin,
fosfomycin, ICU-acquired infection, mortality, ventilator-associ-
ated pneumonia
Original Submission: 30 December 2008; Revised Submission:
19 February 2009; Accepted: 18 March 2009
Editor: D. Mack
Article published online: 20 August 2009
Clin Microbiol Infect 2010; 16: 184–186
10.1111/j.1469-0691.2009.02921.x
Corresponding author and reprint requests: A. Michalopoulos,
Edison 9, Edison Hill. Pallini, 15351. Athens, Greece
E-mail: amichalopoulos@hol.gr
The incidence of infections caused by multidrug-resistant
(MDR) Gram-negative bacteria has increased worldwide dur-
ing the last decade [1–3]. There are reports dealing with
intensive care unit (ICU)-acquired infections caused by MDR
Klebsiella pneumoniae [4,5]. The shortage of new antimicrobial
agents has led clinicians to reconsider the potential value
of old antibiotic compounds (e.g. polymyxins, fosfomycin,
tetracyclines, etc.) in the treatment of MDR Gram-negative
bacterial infections.
The present study aimed to examine the effectiveness and
safety of fosfomycin administered in critically ill patients
suffering from ICU-acquired infections caused by carbape-
nem-resistant K. pneumoniae (CRKP).
We prospectively enrolled all patients who received
intravenous fosfomycin (IF) for treatment of ICU-acquired
infections caused by CRKP from 1 May 2008 to 15 December
2008 in the ICU at ‘Henry Dunant’ Hospital, in Athens. The
study was approved by the Institutional Review Board of the
hospital.
The daily dosage of IF was 4 g administered via a central
venous catheter four times daily in patients with normal
renal function. In elderly patients (>70 years) and in patients
with renal failure, the daily dosage was 2 g administered four
times daily. All patients received Infectofos ﬂ 2 g containing
2.64 g fosfomycin-sodium (Infectopharm Arzneimittel und
Consilium GmgH, Heppenheim, Germany).
Data for several variables, including demographics, reason
for ICU admission, Acute Physiology and Chronic Health
Evaluation (APACHE) II score upon ICU admission and com-
orbidities, were recorded in patients receiving IF. Renal and
liver function tests were recorded just prior to the initiation
of IF and every day during the entire treatment period. The
dosage of IF, the duration of treatment and any adverse
event related to IF, as well as data regarding bacteriological
and clinical response of infections, ICU length of stay and
patient outcome, were also recorded.
Standard criteria for deﬁnitions of comorbidities, nosoco-
mial infections, multidrug resistance and outcome parameters
were employed in accordance with previous studies [6,7].
CRKP strains were tested using the disc diffusion test for
susceptibility to fosfomycin. The results were interpreted as
showing susceptibility of isolated K. pneumoniae to fosfomycin
when the zone of inhibition was ‡16 mm.
The primary endpoint of the study was all-cause in-
hospital mortality. Secondary endpoints included clinical and
bacteriological outcome of infections and the occurrence of
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any adverse event during IF. Assessment of effectiveness and
safety was made at the end of fosfomycin treatment.
Eleven patients receiving IF for treatment of ICU-acquired
infections caused by a CRKP susceptible to fosfomycin were
studied. During this period, 658 patients (29.8% females)
with a mean ± SD age of 66.6 ± 13.7 years were admitted
to the ICU, with a mean stay of 3.8 days and an ICU mortal-
ity rate of 6.9%.
Table 1 shows the demographic and clinical characteristics
of patients. The mean APACHE II score was 23.4 ± 4.9. The
mean ± SD ICU stay and mean hospital stay were 40.5 ±
31.7 days and 111.5 ± 97.5 days, respectively.
All patients developed multiple ICU-acquired infections as
a result of Gram-negative pathogens from different sites
preceding the episode caused by the CRK and received anti-
biotics for a prolonged period prior to the inclusion of IF.
These episodes were bacteraemia (n = 2), ventilator-asso-
ciated pneumonia (VAP) and bacteraemia (n = 3), VAP and
urinary tract infection (UTI) (n = 2), UTI (n = 2), bactera-
emia and wound infection (n = 1) and wound infection
(n = 1). The median time for development of infection as a
result of CRKP was 27 (range 21–208) days after the
patient’s admission to the hospital.
Fosfomycin was administered in combination with colistin
(n = 6), gentamicin (n = 3) and piperacillin/tazobactam
(n = 1), based on sensitivities. The mean ± SD duration of IF
administration was 14.0 ± 5.6 days. There was a good bacte-
riological and clinical outcome of infection for all patients.
All-cause hospital mortality was 18.2%. No patient developed
relapse of infection because of this pathogen. All patients tol-
erated IF well, without renal or liver function test abnormali-
ties. Serum urea and creatinine levels on the day just prior
to fosfomycin administration were 91.2 ± 54.2 and
1.4 ± 0.5 mg/dL, respectively. At the end of IF administra-
tion, these corresponding values were 57.7 ± 24.1 and
1.3 ± 0.6 mg/dL, respectively. No patient experienced any
other adverse event related to the administration of fosfo-
mycin. In particular, none of the patients presented signs of a
hypersensitivity reaction, skin rash or venous thrombosis.
No patient developed a superinfection, including Clostridium
difﬁcile-associated diarrhoea and pseudomembranous colitis.
The main ﬁndings of this study were that all patients
receiving IF had good bacteriological and clinical responses
Furthermore, no patient experienced adverse-events related
to IF.
It is noteworthy that recent studies report isolates of
K. pneumoniae emerging in ICU patients that are colistin-
resistant or pan-drug-resistant pathogens [4,6,8,9]. Previous
studies report susceptibility of extended-spectrum-b-lacta-
mases (ESBL)-producing K. pneumoniae to fosfomycin [10].
Falagas et al. [11] reported that the K. pneumoniae strains
producing both ESBLs and metallo-b-lactamases exhibited
the greatest susceptibility to fosfomycin, with a unimodal dis-
tribution of MICs, across the range 8–64 mg/L, with an
MIC50 of 16 mg/L and an MIC90 of 32 mg/L. Klebsiella strains
have shown a high spontaneous mutation rate for glpT or
uhpT genes and this trait could affect monotherapy with
fosfomycin [12].
It is considered that treatment with fosfomycin is free
from the nephrotoxicity that characterizes treatment with
aminoglycosides. Animal studies have demonstrated that
fosfomycin has a protective effect against nephrotoxicity as
a result of treatment with aminoglycosides by inhibiting
aminoglycoside-induced histamine release from mast-cell
destruction [13].
The present study has several limitations. The main short-
coming of the study is the small number of patients who
were treated with IF, thus not permitting any deﬁnitive con-
clusions and not allowing examination of the comparative
effectiveness and toxicity of fosfomycin when combined with
other antibiotics. Furthermore, there are limitations in the
validity of MIC values of fosfomycin according to the meth-
odology used.
In addition, the disc diffusion method used has an error
rate of approximately 15% compared to reference methods
[14]. However, this is the ﬁrst study in which the effective-
ness and safety of high doses of IF were examined.
In conclusion, fosfomycin may be considered as another
choice for the treatment of infections caused by CRKP in
adult patients, especially in combination with other antibiot-
ics, because of its unique mechanism of action, and its
favourable safety proﬁle.
TABLE 1. Demographic and clinical characteristics for the
patients studied (n = 11)
General features Entire group
Female gender, n (%) 6 (54.5)
Mean ± SD age, years 67.5 ± 14.5
Previous surgery, n (%) 5 (45.4)
Underlying disease
Diabetes mellitus 3 (27.2)
Chronic obstructive pulmonary disease 3 (27.2)
Transfer from another institution, n (%) 3 (27.2)
APACHE II score on ICU admission (mean ± SD) 23.4 ± 4.9
Previous antibiotic courses during the same
hospitalization period, median (range)
3 (2–7)
Number of organ dysfunctions, median (range) 3 (2–5)
Length of hospital stay before isolation of




Mechanical ventilation for >48 h, n (%) 11 (100)
Total length of ICU stay, median (range) (days) 31 (4–107)
Total length of hospital stay, median (range) (days) 86 (20–330)
APACHE, Acute Physiology and Chronic Health Evaluation score; ICU, intensive
care unit.
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Abstract
VIM-6, previously reported in two strains from Singapore recov-
ered in 2000, was detected in 16 isolates collected in 2006 in
India (12 isolates), Indonesia (two), Korea and the Philippines
(one each). High genetic variability was observed among VIM-6-
producing isolates (12 ribotypes and 11 pulsed-ﬁeld gel electro-
phoresis types), but clones were observed in India and Indone-
sia; blaVIM-6-carrying integrons of 3.9 kb and 5 kb were detected,
and two of ﬁve Indian hospitals yielded isolates with both integ-
rons. These two integrons, blaVIM-6 was located in the ﬁrst posi-
tion, followed by blaOXA-10 and aacA4. The 5-kb integrons also
harboured aadA1 and a 331-bp open reading frame encoding a
putative efﬂux pump.
Keywords: Asia-Paciﬁc, metallo-b-lactamases, Pseudomonas aeru-
ginosa, SENTRY, VIM
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Acquired metallo-b-lactamase (MBL)-producing isolates have
been increasingly reported in the Asia-Paciﬁc (APAC) region.
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